Iberoamerican Journal of Medicine
Published April 5, 2020 | Version v1
Journal article Open

Coronavirus (COVID-19): A new pandemic

Creators

  • 1. Regulatory Affairs Officer, Innova Captab Limited, Solan, Himachal Pradesh, India
  • 2. Department of Phamaceutical Analysis, Royal College of Pharmacy and Health Science Berhampur, Odisha, India

Description

.

Files

Coronavirus (COVID-19) A new pandemic_Kumar.pdf

Files (479.9 kB)

Name Size Download all
md5:2267c2d0fb95e5f512fc29dbcbf1ccfa
479.9 kB Preview Download

Additional details

References

  • Wolrd Health Organization. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
  • Wolrd Health Organization. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
  • Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. doi: 10.1038/s41422-020-0282-0.
  • Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.
  • Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396). doi: 10.1126/scitranslmed.aal3653.
  • Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020:105932. doi: 10.1016/j.ijantimicag.2020.105932.
  • Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa237.
  • Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. doi: 10.5582/bst.2020.01047.
  • Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of IBEROAMERICAN JOURNAL OF MEDICINE 00 (2020) XXX–XXX 3 an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949.